Martin Albornoz, MD
Interventional Cardiology · Baltimore, MDNPI 1780687178
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,091 of the $3,991 with a category attached, or 77.4%. 19 manufacturers reported payments, led by Medtronic at 41.8% of the total. Reporting peaked in 2024 at $2,056 and has fallen 90.5% since, to $195 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MD, where the typical reported total is $7,370.
Across 141 payments — averaging $28.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novartis$383
- Abiomed$324
- Boehringer Ingelheim$297
- Boston Scientific$287
- Gilead$192
- plus $840 from 13 others
Across 97 payments — averaging $4108.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$288K
- Alnylam Pharmaceuticals Inc.$111K
What the payments were for
- Travel & lodging$89222%
- Food & beverage$3,09177%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 26 | $1,668 |
| Novartis | 22 | $383 |
| Abiomed | 4 | $324 |
| Boehringer Ingelheim | 18 | $297 |
| Boston Scientific | 4 | $287 |
| Gilead | 22 | $192 |
| Johnson & Johnson | 15 | $171 |
| Shockwave Medical, Inc | 1 | $124 |
| Amgen | 7 | $118 |
| E.r. Squibb & Sons, L.L.C. | 4 | $86 |
| Novo Nordisk | 4 | $81 |
| AstraZeneca | 4 | $60 |
| Abbott | 3 | $51 |
| Biosense Webster, Inc. | 1 | $39 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Atricure, Inc. | 1 | $29 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Philips North America LLC | 1 | $16 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,991 in reported general payments places this provider in the 25th percentile of 71 interventional cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 226 | $300,966 |
| VyndamaxTafamidis | 13 | $288,702 |
| JardianceEmpagliflozin | 182 | $255,710 |
| EntrestoSacubitril/Valsartan | 173 | $227,268 |
| XareltoRivaroxaban | 109 | $150,058 |
| FarxigaDapagliflozin Propanediol | 48 | $63,466 |
| Repatha SureclickEvolocumab | 27 | $24,786 |
| MultaqDronedarone Hcl | 18 | $20,928 |
| Praluent PenAlirocumab | 20 | $17,827 |
| VerquvoVericiguat | 15 | $15,478 |
| VascepaIcosapent Ethyl | 15 | $14,194 |
| Repatha SyringeEvolocumab | 13 | $13,882 |
| Ezetimibe | 175 | $7,970 |
| Metoprolol Succinate | 425 | $7,718 |
| Ranolazine ErRanolazine | 63 | $7,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $12 | $589,667239 claims |
| Boehringer IngelheimJardiance | $297 | $255,710182 claims |
| NovartisEntresto | $383 | $227,268173 claims |
| Johnson & JohnsonXarelto | $171 | $150,058109 claims |
| AstraZenecaFarxiga | $60 | $63,46648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 71 interventional cardiology providers in Maryland.
Other interventional cardiology in Baltimore
- Aloke FinnBaltimore$575K
- John WangBaltimore$138K
- Diljon ChahalBaltimore$78K
- Jon ResarBaltimore$40K
- Faisal RahmanBaltimore$36K
- Matthew VossBaltimore$33K
- Hooman BakhshiBaltimore$32K
- Daniel AmbinderBaltimore$32K
- Rani HasanBaltimore$22K
- Ajar KocharBaltimore$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.